Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Large Increase in Short Interest

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 56,865 shares, a growth of 91.6% from the August 15th total of 29,679 shares. Based on an average daily volume of 4,765,370 shares, the short-interest ratio is currently 0.0 days. Approximately 10.1% of the shares of the company are sold short.

Institutional Investors Weigh In On Jupiter Neurosciences

A number of institutional investors have recently bought and sold shares of JUNS. Allen Capital Group LLC bought a new position in shares of Jupiter Neurosciences in the fourth quarter worth about $31,000. Yorkville Advisors Global LP bought a new stake in Jupiter Neurosciences during the 4th quarter valued at approximately $135,000. Finally, Vestor Capital LLC raised its stake in Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares during the period.

Analyst Ratings Changes

Several brokerages recently issued reports on JUNS. Wall Street Zen upgraded shares of Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jupiter Neurosciences currently has an average rating of “Sell”.

Jupiter Neurosciences Trading Down 11.7%

Jupiter Neurosciences stock traded down $0.40 during midday trading on Tuesday, hitting $3.01. The stock had a trading volume of 57,792 shares, compared to its average volume of 382,749. The firm’s fifty day moving average is $7.36 and its two-hundred day moving average is $19.06. The company has a market capitalization of $2.75 million, a PE ratio of -0.16 and a beta of 1.81. Jupiter Neurosciences has a 52-week low of $2.88 and a 52-week high of $137.96.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings results on Friday, August 14th. The company reported ($5.06) earnings per share for the quarter, missing the consensus estimate of ($3.75) by ($1.31). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.40 million.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.